Using a Trop2-Targeting Near-Infrared Molecular Probe to Identify Non-Muscle-Invasive Bladder Cancer During Surgery

What this Trial Is About

Bladder cancer is a common malignancy, especially among men in the United States, with most patients presenting with non-muscle-invasive bladder cancer NMIBC. Current diagnosis and treatment methods, including white light cystoscopy and transurethral resection of bladder tumors, have a high recurrence rate and can miss some tumors. Researchers are evaluating a novel near-infrared fluorescence imaging probe, called TTP-ICG, which targets Trop2 to help distinguish cancerous tissue from non-cancerous tissue during surgery. The study involves soaking excised bladder tissues in solutions with different concentrations of TTP-ICG for varying times, followed by rinsing and drying. Using a specialized imaging system, researchers will capture fluorescence images to analyze how well the probe highlights cancer tissues compared to surrounding tissues. Additional tests will include staining and immunohistochemistry to confirm the imaging results. Participants will undergo surgery as planned, and their removed tissues will be processed with the TTP-ICG probe. Researchers will assess the ability of this method to differentiate cancer from non-cancer tissue and compare imaging results with pathological diagnoses. The primary outcome is to measure differentiation between bladder cancer and adjacent tissue within six months. Safety and study participation will be monitored throughout, with study completion expected by late 2025.

Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer